MiniMed Group
Valuation each multiple against its own 5-year range
Vs. peers Medical Instruments & Supplies
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| MiniMed Group (MMED) | 4.50B | -14.21 | 1.24 | 0.00% |
| Intuitive Surgical (ISRG) | 138.33B | 48.25 | 8.65 | 0.00% |
| Becton Dickinson & Co (BDX) | 57.96B | 52.02 | 2.35 | 1.97% |
| Alcon (ALC) | 35.92B | 54.24 | 1.64 | 0.48% |
| ResMed (RMD) | 33.14B | 21.46 | 5.57 | 1.04% |
| Medline (MDLN) | 32.55B | 57.52 | 2.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 8.5% below Morningstar's fair value estimate.
Fair value
Minimed Group Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 4% premium over our quantitative fair value estimate of $17.37 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's lack of profitability decreases our quantitative valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's cash flow yield of -0.4% lies in the bottom 30% compared with global peers. At the current valuation, the yield of cash flow from operations to investors looks paltry. We believe this is a sign that shares could be overvalued.
On a different note, the company's liquidity is reassuring. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. The firm's median trading volume over the past 60 days, for example, sits in the top 20% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is overvalued, this outperformance had a positive impact on our valuation estimate.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:47:52 · For reference only, not investment advice and not tailored to your situation.
MiniMed Group discussion 0 comments